Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ARTL NASDAQ:BMRA NASDAQ:DWTX NASDAQ:VAXX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARTLArtelo Biosciences$10.20-14.0%$10.63$4.92▼$28.60$7.19M1.36565,339 shs612,033 shsBMRABiomerica$3.15-2.8%$3.30$1.93▼$10.16$8.23M0.2670,894 shs18,448 shsDWTXDogwood Therapeutics$4.85+0.2%$4.91$1.62▼$29.28$9.27M1.825,068 shs4,210 shsVAXXVaxxinity$0.00$0.01$0.00▼$0.20$13K-23.965,046 shs264 shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARTLArtelo Biosciences0.00%-25.71%-5.51%+66.67%+25.93%BMRABiomerica0.00%-19.44%-4.69%-12.74%+18.99%DWTXDogwood Therapeutics0.00%+1.68%+0.62%-3.39%+484,999,900.00%VAXXVaxxinity0.00%-99.00%-99.67%-99.78%-99.75%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationARTLArtelo Biosciences2.2361 of 5 stars3.83.00.00.01.70.00.6BMRABiomerica0.1975 of 5 stars0.03.00.00.00.60.80.0DWTXDogwood Therapeutics1.4369 of 5 stars3.50.00.00.01.10.00.6VAXXVaxxinityN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceARTLArtelo Biosciences 3.60Strong Buy$25.00145.10% UpsideBMRABiomerica 0.00N/AN/AN/ADWTXDogwood Therapeutics 3.00Buy$10.00106.19% UpsideVAXXVaxxinity 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest VAXX, ARTL, BMRA, and DWTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/8/2025ARTLArtelo BiosciencesD Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold ➝ Strong-Buy7/8/2025ARTLArtelo BiosciencesD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold ➝ Buy$20.006/11/2025ARTLArtelo BiosciencesD Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold6/6/2025ARTLArtelo BiosciencesD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$36.00(Data available from 8/3/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookARTLArtelo BiosciencesN/AN/AN/AN/A$5.31 per shareN/ABMRABiomerica$5.41M1.48N/AN/A$3.13 per share1.01DWTXDogwood TherapeuticsN/AN/AN/AN/A($7.56) per shareN/AVAXXVaxxinityN/AN/AN/AN/A$0.11 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateARTLArtelo Biosciences-$9.83M-$17.94N/AN/AN/AN/A-226.99%-164.61%8/12/2025 (Estimated)BMRABiomerica-$5.98M-$2.32N/A∞N/A-85.42%-85.90%-61.06%8/27/2025 (Estimated)DWTXDogwood Therapeutics-$12.35M-$18.04N/AN/AN/AN/AN/A-34.74%8/6/2025 (Estimated)VAXXVaxxinity-$56.93M-$0.45N/A∞N/AN/AN/AN/AN/ALatest VAXX, ARTL, BMRA, and DWTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025DWTXDogwood Therapeutics-$1.26N/AN/AN/AN/AN/A8/12/2025Q2 2025ARTLArtelo Biosciences-$0.13N/AN/AN/AN/AN/A5/13/2025Q1 2025ARTLArtelo Biosciences-$0.78-$4.32-$3.54-$0.72N/AN/A5/8/2025Q1 2025DWTXDogwood Therapeutics-$0.77-$4.21-$3.44-$8.45N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthARTLArtelo BiosciencesN/AN/AN/AN/AN/ABMRABiomericaN/AN/AN/AN/AN/ADWTXDogwood TherapeuticsN/AN/AN/AN/AN/AVAXXVaxxinityN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioARTLArtelo BiosciencesN/A0.490.49BMRABiomericaN/A3.762.76DWTXDogwood TherapeuticsN/A7.437.43VAXXVaxxinityN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipARTLArtelo Biosciences0.87%BMRABiomerica22.28%DWTXDogwood Therapeutics9.05%VAXXVaxxinity82.95%Insider OwnershipCompanyInsider OwnershipARTLArtelo Biosciences0.83%BMRABiomerica15.00%DWTXDogwood Therapeutics3.90%VAXXVaxxinity64.06%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableARTLArtelo Biosciences5700,000698,000Not OptionableBMRABiomerica602.55 million2.16 millionOptionableDWTXDogwood Therapeutics51.91 million1.84 millionN/AVAXXVaxxinity90126.75 million45.55 millionNot OptionableVAXX, ARTL, BMRA, and DWTX HeadlinesRecent News About These CompaniesBrain healthOctober 24, 2024 | newsweek.comNTreatment Trials in Alzheimer's DiseaseSeptember 30, 2024 | msn.comIs Vaxxinity Inc (VAXX) Stock a Good Investment?September 19, 2024 | aaii.comACongress makes $4.5 trading stocks in a day; Here's the biggest winnersJuly 4, 2024 | finbold.comFVaxxinity UB-312 Parkinson's Trial Results Published in Nature MedicineJune 20, 2024 | globenewswire.comWhy Is Vaxxinity (VAXX) Stock Up 39% Today?May 3, 2024 | investorplace.comWhy Is Vaxxinity (VAXX) Stock Down 58% Today?April 22, 2024 | investorplace.comVaxxinity Plans to Delist Shares From NasdaqApril 19, 2024 | marketwatch.comVaxxinity Issues Shareholder LetterApril 19, 2024 | globenewswire.comVaxxinity Announces Intention to Voluntarily Delist and Deregister its Class A Common StockApril 19, 2024 | globenewswire.comVaxxinity to Present Clinical Data at the Annual Academy of Neurology 2024 Annual MeetingMarch 28, 2024 | globenewswire.comVAXX Stock Earnings: Vaxxinity Beats EPS for Q4 2023March 27, 2024 | investorplace.comVaxxinity Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Corporate UpdatesMarch 27, 2024 | globenewswire.comVaxxinity Announces Positive Target Engagement Data from Phase 1 Clinical Trial for Parkinson's Disease at AD/PD™ 2024March 7, 2024 | globenewswire.comVaxxinity’s Heart Health Innovation to Reduce LDL Cholesterol LevelsFebruary 15, 2024 | finance.yahoo.comVaxxinity’s Cholesterol Vaccine Candidate Successfully Lowers LDL-C: Preclinical Data PublishedFebruary 15, 2024 | finance.yahoo.comVaxxinity's Cholesterol Vaccine Candidate Successfully Lowers LDL-C: Preclinical Data PublishedFebruary 15, 2024 | globenewswire.comVaxxinity to Present Clinical and Preclinical Pipeline Data at AD/PD 2024February 13, 2024 | finance.yahoo.comVaxxinity, UF Join Forces Against Neurodegenerative DiseasesJanuary 30, 2024 | finance.yahoo.comVaxxinity Announces Research Collaboration on Active Immunotherapies for Neurodegenerative Diseases with University of FloridaJanuary 30, 2024 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeVAXX, ARTL, BMRA, and DWTX Company DescriptionsArtelo Biosciences NASDAQ:ARTL$10.20 -1.66 (-14.00%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$10.44 +0.24 (+2.34%) As of 08/1/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, develops and commercializes therapeutics that target lipid-signaling pathways in the United States. It's product candidate pipeline includes ART27.13, a synthetic dual cannabinoid G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of anorexia associated with cancer; ART12.11, a synthetic cannabidiol cocrystal for the treatment anxiety, post-traumatic stress disorder, epilepsy, inflammatory bowel disease, and other potential indications; and ART26.12, a fatty acid binding protein 5 inhibitor for treating chemotherapy induced peripheral neuropathy, diabetic neuropathy, prostate cancer and breast cancer, pain, dermatologic conditions, and anxiety disorders. The company was formerly known as Reactive Medical, Inc. and changed its name to Artelo Biosciences, Inc. in April 2017. Artelo Biosciences, Inc. was incorporated in 2011 and is based in Solana Beach, California.Biomerica NASDAQ:BMRA$3.15 -0.09 (-2.78%) Closing price 08/1/2025 03:59 PM EasternExtended Trading$3.32 +0.18 (+5.56%) As of 08/1/2025 07:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Biomerica, Inc., a biomedical technology company, develops, patents, manufactures, and markets diagnostic and therapeutic products for the detection and/or treatment of medical conditions and diseases worldwide. The company's diagnostic test kits are used to analyze blood, urine, nasal or fecal specimens from patients in the diagnosis of various diseases, food intolerances, and other medical complications; or to measure bacteria, hormones, antibodies, antigens, or other substances which may exist in the human body, stools, or blood in extremely small concentrations. It primarily sells its products for gastrointestinal diseases, food intolerances, and various esoteric tests at the physicians' offices and over-the-counter drugstores, and hospital/clinical laboratories. The company is also developing InFoods IBS, that uses a simple blood sample to identify patient-specific foods which may alleviate irritable bowel syndrome symptoms; and H. Pylori diagnostic test that indicates if a patient is infected with the H. Pylori bacteria. In addition, it develops products to indicate if a person has been infected by COVID-19. Biomerica, Inc. was incorporated in 1971 and is headquartered in Irvine, California.Dogwood Therapeutics NASDAQ:DWTX$4.85 +0.01 (+0.21%) Closing price 08/1/2025 03:54 PM EasternExtended Trading$4.78 -0.07 (-1.55%) As of 08/1/2025 06:11 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Dogwood Therapeutics, Inc. is a development-stage biotechnology company, which engages in developing therapeutics for pain and fatigue illness. Its product includes Halneuron. It focuses on antiviral therapies IMC-1 and IMC-2 to treat diseases associated with a viral triggered abnormal immune response such as Long-COVID and fibromyalgia. The company was founded on February 28, 2012 is headquartered in Alpharetta, GA.Vaxxinity NASDAQ:VAXX$0.0001 0.00 (0.00%) As of 08/1/2025 03:29 PM EasternVaxxinity, Inc., a biotechnology company, focuses on developing product candidates for human use in the fields of neurology, cardiovascular diseases, and coronaviruses in the United States. Its product pipeline comprises UB-311, which is in phase 2 clinical trial that targets toxic forms of aggregated amyloid-b in the brain to fight alzheimer's disease; UB-312, which is in phase 1 clinical trial that targets toxic forms of aggregated a-synuclein in the brain to fight parkinson's disease and other synucleinopathies, such as Lewy body dementia and multiple system atrophy; and VXX-301, which is in preclinical trial, an anti-tau product candidate for various neurodegenerative conditions, including alzheimer's disease, traumatic brain injury, and chronic traumatic encephalopathy. It also develops VXX-401, which is phase 1 clinical trial that targets proprotein convertase subtilisin/kexin type 9 serine protease to lower low-density lipoprotein cholesterol and reduce the risk of cardiac events; UB-313 that targets calcitonin gene-related peptide to fight migraines; and UB-612, neutralizes the SARS-CoV-2 virus and is in phase 3 clinical trial. The company was incorporated in 2021 and is headquartered in Merritt Island, Florida. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/28 - 08/01 Alphabet Gains Momentum as Sentiment on Wall Street Improves Amazon's Earnings: What Comes Next and How to Play It Apple Stock: Big Earnings, Small Move—Time to Buy? Tesla Teams With Samsung—Will Other Chipmakers Follow? Will Hims & Hers Fall Along With Novo Nordisk? UPS's 7.5% Dividend: A Blue-Chip Stock on a Once-in-a-Decade Sale Is PG&E an AI Power Play? Why Options Traders Are Betting Big Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
